Abstract
Background: Arterial hypertension (AH) and peripheral arterial disease (PAD) frequently coincide. While significant attention is paid to AH, PAD is often underestimated. It is known that both AH and PAD present high cardiovascular risks for ischemic events. To date, the use of the most common anti-hypertensive drugs in PAD patients is still under debate.
Methods: Data from studies of large populations and minor cohorts of patients show AH and PAD together or PAD alone. Results: cardiovascular and renal outcomes for PAD patients show lowered arterial pressure. We cannot rank the class of anti-hypertensive drugs recommended for PAD patients with AH. However, optimum targeted anti-hypertensive therapy is strongly recommended by cardiology guidelines.
Conclusion: comprehensive cardiovascular protection is the most important goal in using anti-AH drugs in PAD together with other drugs such as anti-platelets and statins.
Keywords: Arterial hypertension, peripheral arterial disease, cardiovascular risks, anti-hypertensive drugs, arterial pressure, anti-hypertensive therapy.
Current Pharmaceutical Design
Title:How to Treat Patients with Essential Hypertension and Peripheral Arterial Disease
Volume: 23 Issue: 31
Author(s): Salvatore Santo Signorelli*
Affiliation:
- Department of Clinical and Experimental Medicine, University of Catania; General Medicine Division, University Hospital “G.Rodolico. Catania,Italy
Keywords: Arterial hypertension, peripheral arterial disease, cardiovascular risks, anti-hypertensive drugs, arterial pressure, anti-hypertensive therapy.
Abstract: Background: Arterial hypertension (AH) and peripheral arterial disease (PAD) frequently coincide. While significant attention is paid to AH, PAD is often underestimated. It is known that both AH and PAD present high cardiovascular risks for ischemic events. To date, the use of the most common anti-hypertensive drugs in PAD patients is still under debate.
Methods: Data from studies of large populations and minor cohorts of patients show AH and PAD together or PAD alone. Results: cardiovascular and renal outcomes for PAD patients show lowered arterial pressure. We cannot rank the class of anti-hypertensive drugs recommended for PAD patients with AH. However, optimum targeted anti-hypertensive therapy is strongly recommended by cardiology guidelines.
Conclusion: comprehensive cardiovascular protection is the most important goal in using anti-AH drugs in PAD together with other drugs such as anti-platelets and statins.
Export Options
About this article
Cite this article as:
Signorelli Santo Salvatore*, How to Treat Patients with Essential Hypertension and Peripheral Arterial Disease, Current Pharmaceutical Design 2017; 23 (31) . https://dx.doi.org/10.2174/1381612823666170608083605
DOI https://dx.doi.org/10.2174/1381612823666170608083605 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuroinflammatory Markers in Spontaneously Hypertensive Rat Brain: An Immunohistochemical Study
CNS & Neurological Disorders - Drug Targets Coronary Artery Disease and End-Stage Renal Disease - A Clinical Perspective
Current Hypertension Reviews Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Clinically Relevant Drug Interactions with Anti-Alzheimer's Drugs
CNS & Neurological Disorders - Drug Targets Attenuation of Diabetes-induced Cardiac and Subcellular Defects by Sulphur-containing Amino Acids
Current Medicinal Chemistry Genetic Polymorphisms in the Growth Hormone Receptor: Impact on Growth Response and Disease Susceptibility
Current Pharmacogenomics and Personalized Medicine Optimising the Use of Non-Invasive Ventilation in the Intensive Care Setting
Current Respiratory Medicine Reviews Effects of Pterostilbene on Diabetes, Liver Steatosis and Serum Lipids
Current Medicinal Chemistry Protective Effects of Anesthetics on Vascular Function Related to K<sup>+</sup> Channels
Current Pharmaceutical Design Goal Directed Fluid Therapy
Current Pharmaceutical Design Resveratrol as a Supplemental Therapeutic in Cardiovascular and Metabolic Syndromes: A Critical Review
Current Nutrition & Food Science Bivalirudin: Alternative Anticoagulation During Cardiopulmonary Bypass in Patients with Heparin-Induced Thrombocytopenia
Recent Patents on Cardiovascular Drug Discovery Current Status of Hormone Replacement Therapy in Post Menopausal Women
Current Drug Therapy Sildenafil and Cardioprotection
Current Pharmaceutical Design A Prevention of Pre-eclampsia with the Use of Acetylsalicylic Acid and Low-molecular Weight Heparin – Molecular Mechanisms
Current Pharmaceutical Biotechnology The Effect of Ethyl Acetate Extract of Pomelo Mix on Systemic Exposure of Verapamil in Rabbits
Drug Metabolism Letters Sesamol Induces Apoptosis by Altering Expression of Bcl-2 and Bax Proteins and Modifies Skin Tumor Development in Balb/c Mice
Anti-Cancer Agents in Medicinal Chemistry Clinically Significant Proteinuria Following the Administration of Sirolimus to Renal Transplant Recipients
Drug Metabolism Letters Coronary Artery Disease and Endothelial Dysfunction: Novel Diagnostic and Therapeutic Approaches
Current Medicinal Chemistry Potential Applications of FDG-PET/CT in COPD: A Review of the Literature
Current Molecular Imaging (Discontinued)